Blog

 Ensure efficient and effective delivery of medicines to fight one of the deadliest diseases in the world: malaria Over the past several decades, malaria has remained one of the deadliest diseases in many parts of the world. Although there have been decades of investment in health interventions, such as bed nets and medication, malaria continues […]

 Malaria continues to pose one of humanity’s most pressing public health challenges, especially in sub-Saharan Africa. Despite laudable progress in recent years, providing anti-malaria medicines to every last child continues to represent a daunting challenge. After all, it’s a tall order to ask us to distribute anti-malaria medicines to 24 million children. With the right

 Malaria is a mosquito-borne disease, transmitted by anopheles mosquitoes. This disease remains a major global public health problem. While malaria can potentially affect people of any age group, under-five children are the most vulnerable group. In most settings, particularly in sub-Saharan Africa, malaria continues to be among the most common causes of morbidity and mortality

 Millions continue to fall ill annually from malaria, a deadly mosquito-borne disease, and any efforts to successfully manage and eradicate malaria depend entirely on the availability of high-quality, efficacious, and safe anti-malaria drugs. This article examines the various steps taken to ensure that anti-malaria drugs meet the required quality, efficacy, and safety guarantees. The Importance

 Although its origins are shrouded in mystery, it comes as no surprise that malaria, the lethal parasitic disease passed on by the bites of infected mosquitoes, continues to plague the world’s inhabitants, causing millions of deaths every year. Despite heroic attempts at prevention and treatment over the preceding decades and centuries, malaria continues to threaten

 There is still no easy or light-hearted issue in the world of public health, and none is more globally far-reaching or urgent than malaria. Every year, there are millions and millions of cases of mosquito-borne illness across the world – and stopping it relies on anti-malaria drugs getting into people’s hands. And for that to

 Malaria, a major killer transmitted by mosquitoes of the genus Anopheles, still represents a huge challenge for global health. Despite the important advances registered in recent years, millions of people still suffer every year, and millions continue to die, especially across sub-Saharan Africa. Distributing medicines in large amounts and reaching the people in need is

 Malaria continues to be one of the most pressing global health issues, particularly in sub-Saharan Africa, where the disease affects mostly children under five, despite the availability of prevention and treatment approaches. The unequal access to anti-malaria medications maintains the unequal burden of this deadly disease. Until we address disparities through inclusion, children will continue

 More than 400,000 people died of malaria last year; hundreds of thousands more are affected each year by what is surely the most dreaded of all tropical diseases, transmitted by the bite of infected female Anopheles mosquitoes. Despite decades of progress, malaria remains a scourge of the human race, mainly in sub-Saharan Africa. For decades,

 The world’s drug supply chain has been under extreme pressure over the past three years. The COVID-19 pandemic wrecked global supply chains, in part exposing tensions between major powers. Natural disasters like floods and volcanic eruptions are occurring more often, while new challenges to supply chains now seem to emerge almost daily. Arguably, the biggest